Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany Farchione

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 28, 2021
Regulatory considerations in drug development for autism spectrum disordersValentina Mantua, Tiffany Farchione
JAMA|March 16, 2019
Challenges in Research on Suicide PreventionJean Kim, Michael Davis, Tiffany Farchione
The New England Journal of Medicine|May 23, 2019
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New ClassJean Kim, Tiffany Farchione, Andrew Potter, et al.
Psychiatric Research and Clinical Practice|September 14, 2022
Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug AdministrationMathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, et al.
JAMA Psychiatry|July 2, 2020
Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia MedicationsIslam R Younis, Mathangi Gopalakrishnan, Mitchell Mathis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 20, 2017
Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adultsLiang Li, Yaning Wang, Ramana S Uppoor, et al.
The Journal of Clinical Psychiatry|May 12, 2017
The US Food and Drug Administration's Perspective on the New Antipsychotic PimavanserinMitchell V Mathis, Brendan M Muoio, Paul Andreason, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|November 26, 2011
Differential patterns of abnormal activity and connectivity in the amygdala-prefrontal circuitry in bipolar-I and bipolar-NOS youthCecile D Ladouceur, Tiffany Farchione, Vaibhav Diwadkar, et al.
Archives of General Psychiatry|February 5, 2002
Prefrontal cortical volume in childhood-onset major depression: preliminary findingsCarla L Nolan, Gregory J Moore, Rachel Madden, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 23, 2021
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directionsJames T McCracken, Evdokia Anagnostou, Celso Arango, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 28, 2021
Regulatory considerations in drug development for autism spectrum disordersValentina Mantua, Tiffany Farchione
JAMA|March 16, 2019
Challenges in Research on Suicide PreventionJean Kim, Michael Davis, Tiffany Farchione
The New England Journal of Medicine|May 23, 2019
Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New ClassJean Kim, Tiffany Farchione, Andrew Potter, et al.
Psychiatric Research and Clinical Practice|September 14, 2022
Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug AdministrationMathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, et al.
JAMA Psychiatry|July 2, 2020
Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia MedicationsIslam R Younis, Mathangi Gopalakrishnan, Mitchell Mathis, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 20, 2017
Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adultsLiang Li, Yaning Wang, Ramana S Uppoor, et al.
The Journal of Clinical Psychiatry|May 12, 2017
The US Food and Drug Administration's Perspective on the New Antipsychotic PimavanserinMitchell V Mathis, Brendan M Muoio, Paul Andreason, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|November 26, 2011
Differential patterns of abnormal activity and connectivity in the amygdala-prefrontal circuitry in bipolar-I and bipolar-NOS youthCecile D Ladouceur, Tiffany Farchione, Vaibhav Diwadkar, et al.
Archives of General Psychiatry|February 5, 2002
Prefrontal cortical volume in childhood-onset major depression: preliminary findingsCarla L Nolan, Gregory J Moore, Rachel Madden, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 23, 2021
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directionsJames T McCracken, Evdokia Anagnostou, Celso Arango, et al.
Pageof 2